SAB Biotherapeutics, Inc.: BALYASNY ASSET MANAGEMENT L.P. amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Balyasny Asset Management L.P. amended its Schedule 13G filing on SAB Biotherapeutics, Inc., updating its beneficial ownership stake with the SEC under accession number 0001172661-26-005056. The filing was disclosed via SEC EDGAR. The amendment signals a change in the asset manager's position in the clinical-stage biotech. Investors should watch for the specific share count and percentage disclosed in the filing to gauge whether Balyasny increased, trimmed, or maintained its stake.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Balyasny Asset Management L.P., SAB Biotherapeutics, Inc.